EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Patient‐reported data on the severity of Von Willebrand disease

Calvin B van Kwawegen iD, Karin Fijnvandraat, Marieke J H A Kruip iD, Joke de Meris, Saskia E M Schols, Karina Meijer, Johanna G van der Bom, Marjon H Cnossen, Karin P M van Galen iD, Ferdows Atiq iD, Jeroen Eikenboom, Frank W G Leebeek iD und 1 weitere

Haemophilia · 2024

DOI: 10.1111/hae.15103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2024. Verfasst von Calvin B van Kwawegen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: von Willebrand Diseases, Severity of Illness Index, Patient Reported Outcome Measures, Quality of Life. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stichting Haemophilia, CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient‐reported outcomes (PROs) in VWD.

Aim

The study aimed to investigate the patient‐perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients. Materials and methods Patients participated in a nationwide cross‐sectional study on VWD in the Netherlands (WiN‐study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4‐point scale), bleeding score (BS) and quality of life (QoL).

Results

We included 736 patients, median age of 41.0 years (IQR 23.0–55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self‐reported severity of VWD was categorized as severe ( n = 52), moderate ( n = 171), mild ( n = 393) or negligible ( n = 120). Classification by historically lowest FVIII:C levels < 0.20 IU/mL as a proxy for severe VWD aligned with patient‐reported severity classification with a 72% accuracy. Type 3 VWD (OR = 4.02, 95%CI: 1.72–9.45), higher BS (OR = 1.09, 95%CI: 1.06–1.11), female sex (OR = 1.36, 95%CI: 1.01–1.83), haemostatic treatment in the year preceding study inclusion (OR = 1.53, 95%CI: 1.10–2.13) and historically lowest VWF:Act levels (OR = 0.26, 95%CI: 0.07–1.00) were independent determinants of patient‐reported severity.

Conclusion

This study shows that patient‐reported data provide novel insights into the determinants of experienced disease severity. Our findings highlight the need for studies on PROs with validated questionnaires to assess the burden of VWD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand DiseasesSeverity of Illness IndexPatient Reported Outcome MeasuresQuality of LifeHumansMaleFemaleAdultMiddle AgedCross-Sectional StudiesYoung AdultSurveys and QuestionnairesNetherlandsHemorrhage

Stichwörter der Autor:innen

Von Willebrand diseaseclassificationdisease severitypatient reported outcome measuresquality of life

Autor:innen und Institutionen

  • Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, The Netherlands.
  • Department of Molecular Cellular Hemostasis, Sanquin Research, Amsterdam, The Netherlands.
  • Netherlands Hemophilia Society, Leiden, The Netherlands.
  • Department of Hematology, Radboud University Medical Center, Hemophilia Treatment Centre Nijmegen-Eindhoven-Maastricht, Nijmegen, The Netherlands.
  • Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

ORCID-Profile: Calvin B van Kwawegen, Marieke J H A Kruip, Karin P M van Galen, Ferdows Atiq, Frank W G Leebeek

Förderung

  • Stichting Haemophilia
  • CSL Behring

Zitieren

APA

van Kwawegen, C. B., Fijnvandraat, K., Kruip, M. J. H. A., de Meris, J., Schols, S. E. M., Meijer, K., van der Bom, J. G., Cnossen, M. H., van Galen, K. P. M., Atiq, F., Eikenboom, J., Leebeek, F. W. G., & WiN study group (2024). Patient‐reported data on the severity of Von Willebrand disease. Haemophilia. https://doi.org/10.1111/hae.15103

Vancouver

van Kwawegen CB, Fijnvandraat K, Kruip MJHA, de Meris J, Schols SEM, Meijer K, et al. Patient‐reported data on the severity of Von Willebrand disease. Haemophilia. 2024. doi:10.1111/hae.15103

BibTeX
@article{vanKwawegen2024,
  author = {van Kwawegen, Calvin B and Fijnvandraat, Karin and Kruip, Marieke J H A and de Meris, Joke and Schols, Saskia E M and Meijer, Karina and van der Bom, Johanna G and Cnossen, Marjon H and van Galen, Karin P M and Atiq, Ferdows and Eikenboom, Jeroen and Leebeek, Frank W G and WiN study group, WiN study group},
  title = {Patient‐reported data on the severity of Von Willebrand disease},
  journal = {Haemophilia},
  year = {2024},
  doi = {10.1111/hae.15103}
}
Kostenlos starten →